Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Frontiers in Pharmacology|February 6, 2024
Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancerVicenç Ruiz de Porras, Adrià Bernat-Peguera, Clara Alcon, et al.
BMC Cancer|July 28, 2023
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancerErnest Nadal, Mansoor Saleh, Santiago Ponce Aix, et al.
International Journal of Molecular Sciences|July 29, 2023
Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking SurgeryAndrea Plaja, Iris Teruel, Maria Ochoa-de-Olza, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid TumorsMartin Gutierrez, Victor Moreno, Kimberley M Heinhuis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through ProteogenomicsMaria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, et al.
The Lancet. Oncology|March 7, 2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trialDaniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 CriteriaIgnacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
JAMA Oncology|August 26, 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail StudyEllen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
Pageof 3